Years Active: 2024
Title: David Meininger - Innovator in Antibody Development
Introduction
David Meininger is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target specific antigens. His work has implications for therapeutic applications, especially in cancer treatment.
Latest Patents
David Meininger holds a patent for "Anti-mesothelin antigen-binding molecules and uses thereof." This patent includes antibodies and polypeptides that specifically bind to mesothelin (MSLN), including bispecific antibodies that can bind both MSLN and a T cell antigen, such as CD3. The patent also covers pharmaceutical compositions that comprise these antibodies, nucleic acids encoding them, expression vectors, and host cells for their production. Furthermore, it outlines methods for treating subjects using these innovative antibodies.
Career Highlights
Throughout his career, David Meininger has focused on advancing the understanding and application of antibody technology. His innovative approaches have led to the development of new therapeutic strategies that could potentially improve patient outcomes in various diseases.
Collaborations
David has collaborated with notable colleagues, including Colin Correnti and Christopher Mehlin. These partnerships have enhanced the research and development of his patented technologies, contributing to the advancement of the field.
Conclusion
David Meininger is a pioneering inventor whose work in antibody development has the potential to transform therapeutic approaches in medicine. His contributions are significant in the ongoing quest for effective treatments against diseases like cancer.